For many cell-based vaccines, the precursor monocytes or CD34+ cells are cultured with cytokines to obtain dendritic cells, which are very potent antigen-presenting cells (APCs).
Lee K. Roberts
Advertisement
Articles by Lee K. Roberts
Advertisement
Latest Updated Articles
Cancer Vaccines: Asymptotically Approaching Product ApprovalPublished: August 2nd 2007 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
2
Reducing CAR-T Manufacturing Times and Cost: Q&A with Trenchant’s Jon Ellis
3
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
4
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
5
